No profile data available.
C4 Therapeutics, Inc. (CCCC) is a healthcare company in the medication development research industry, based in Watertown, United States, with about 104 full-time employees.
It reported revenue of $35.95 million for fiscal year 2025, up 1.0% from fiscal year 2024, and net income of -$104.99 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $6.64 million, up 2.8% from a year before. Its market capitalization was $362.92 million as of October 2, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 2, 2026.
, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
C4 Therapeutics reported $35.95 million in revenue for fiscal year 2025, up 1.0% from $35.58 million in fiscal year 2024. In Q2 2026 revenue was $6.64 million.
$362.92 million as of October 2, 2026.
Listed companies of a similar size in the same industry (medication development research) include Recursion Pharmaceuticals, Inc. (RXRX), Absci Corporation (ABSI), Evotec SE (EVO), Molecular Partners AG (MOLN).